english
français
RP2E INRA Université de Lorraine

Publications

Long-term ACE inhibitor/ARB use is associated with severe renal dysfunction and acute kidney injury in patients with severe COVID-19: results from a Referral Center Cohort in the north east of France

Clinical Infectious Diseases, 71(9): pp. 2447-2456.

Oussalah, A., Gleye, S., Clerc Urmes, I., Laugel, E., Callet, J., Barbé, F., Orlowski, S., Malaplate, C., Aimone-gastin, I., Caillierez, B.-M., Merten, M., Jeannesson, E., Kormann, R., Olivier, J.-L., Rodriguez-guéant, R.-M., Namour, F., Bevilacqua, S., Losser, M.-R., Levy, B., Kimmoun, A., Gibot, S., Thilly, N., Frimat, L., Schvoerer, E., Guéant, J.-L.

2020

Background: In patients with severe COVID-19, data are scarce and conflicting regarding whether chronic use of angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) influences disease outcomes. In patients with severe COVID-19, we assessed the association between chronic ACEI/ARB use and the occurrence of kidney, lung, heart, and liver dysfunctions and the severity of the inflammatory reaction as evaluated by biomarkers kinetics, and their association with disease outcomes.

Methods: We performed a retrospective longitudinal cohort study on consecutive patients with newly diagnosed severe COVID-19. Independent predictors were assessed through receiver operating characteristic analysis, time-series analysis, logistic regression analysis, and multilevel modeling for repeated measures.

Results: On the 149 patients included in the study 30% (44/149) were treated with ACEI/ARB. ACEI/ARB use was independently associated with the following biochemical variations: phosphorus >40 mg/L (odds ratio [OR], 3.35, 95% CI, 1.83-6.14), creatinine >10.1 mg/L (OR, 3.22, 2.28-4.54), and urea nitrogen (UN) >0.52 g/L (OR, 2.65, 1.89-3.73). ACEI/ARB use was independently associated with acute kidney injury, AKI stage ≥1 (OR, 3.28, 2.17-4.94). The daily dose of ACEI/ARB was independently associated with altered kidney markers with an increased risk of +25 to +31% per each 10 mg increment of lisinopril-dose equivalent. In multivariable multilevel modeling, UN >0.52 g/L was independently associated with the risk of acute respiratory failure (OR, 3.54, 1.05-11.96).

Conclusions: Patients chronically treated with ACEI/ARB who have severe COVID-19 are at increased risk of acute kidney injury. In these patients, the increase in UN associated with ACEI/ARB use could predict the development of acute respiratory failure.

Imprimer le document

Voir le document sur le site de l'éditeur

179 Publications depuis 2019

Imprimer le listing

2024

ACL - Articles comité de lecture référencés bases de données HCÉRES

2023

ACL - Articles comité de lecture référencés bases de données HCÉRES

2022

ACL - Articles comité de lecture référencés bases de données HCÉRES

2021

ACL - Articles comité de lecture référencés bases de données HCÉRES

ACLN - Articles comité de lecture non-référencés bases de données HCÉRES

2020

ACL - Articles comité de lecture référencés bases de données HCÉRES

ACLN - Articles comité de lecture non-référencés bases de données HCÉRES

2019

ACL - Articles comité de lecture référencés bases de données HCÉRES

ACLN - Articles comité de lecture non-référencés bases de données HCÉRES

Voir les productions antérieures

Toutes les productions scientifiques